Heart Medications

Data from healthcare platforms reveals surge in cardiac consultations, preventive checkups

Prices of 900 formulations are expected to increase to reflect annual change in WPI

Opens floodgates for more generic launches; 40 new brands expected

Global healthcare firm Abbott on Wednesday said it has received approval from the Drugs Controller General of India (DCGI) for its once-a-day formulation, Ivabradine, used for treatment of chronic heart failure and chronic stable angina. The company plans to launch Ivabradine prolonged release tablets in the Indian market in the coming weeks, Abbott said in a statement. This formulation will be more convenient for patients, which will help facilitate treatment adherence with the aim to improve health outcomes, it added. The formulation has been developed at Abbott's innovation & development (I&D) centre in Mumbai, the statement said. "Adherence to therapy is a critical factor to maximize the overall health of people with chronic heart failure or chronic stable angina. We have used the best technology and science to develop this new dosage formulation," Abbott Regional Medical Director Balagopal Nair said. The convenient once-a-day formulation will help improve overall ...

The study finds that training for and finishing a marathon can spruce up arteries, leaving them more flexible, healthy and biologically younger than before, even if runners are older or slow

Millions of Americans have taken the drugs, which are at the center of a widening recall being overseen by the USFDA